2007-06-08-世界卫生组织-WHO_workshop_and_practical_course_on_Human_Papillomavirus_HPV_genotyping_and_HPV16_18_serology_19页_213kb

WHO Workshop and Practical Course on Human Papillomavirus (HPV) Genotyping and HPV16/18 Serology Summary

Introduction and Background

This workshop, organized by WHO in collaboration with the global HPV laboratory network (LabNet), aimed to promote quality laboratory services for HPV surveillance and monitoring, particularly in the context of HPV vaccine introduction and impact evaluation. The mission of LabNet is to enhance international standards for laboratory capabilities through technology support, training, and quality assurance. Specific tasks include providing standardized methods, proficiency panels, and guidance to regional laboratories.

Objectives and Goals

The workshop and practical course focused on discussing laboratory aspects related to HPV vaccine follow-up, surveillance, and standardization. Key objectives were:

• To review and advance the tasks of global and regional reference laboratories.
• To provide theoretical and practical training in HPV DNA genotyping and HPV16/18 serology methodologies.
• To foster collaboration for international standardization and quality control of lab procedures.

Participants and Meeting Structure

Sixteen participants from six WHO HPV reference laboratories and other stakeholders attended. The agenda included theoretical presentations, group discussions, and hands-on practical sessions covering DNA extraction, PCR-based genotyping, ELISA, neutralization assays, and quality control measures. The program was detailed in the Annex, combining sessions on methodologies from various labs.

Key Activities and Learning Outcomes

Participants engaged in various laboratory activities:

• HPV DNA genotyping using consensus primer PCR and reverse hybridization.
• HPV16/18 serology via VLP-based ELISA and pseudovirion neutralization assays.
• Training on techniques from global leaders, including real-time PCR, membrane hybridization, and assay optimization.
  Positive feedback was received, with users appreciating the content's relevance. Suggestions included more time for unfamiliar techniques and further refinement of protocols.

Recommendations and Conclusions

Actionable decisions were made:

• Develop a WHO Laboratory Manual for HPV diagnosis, including chapters on LabNet's role and standardized SOPs.
• Implement essential surveillance components: baseline HPV DNA and serology data collection; reference sample submission for confirmatory testing; and use of serology for pre-vaccination surveys.
• Standardize communication: bi-annual newsletter, updated website, and SharePoint for collaboration.
• Enhance quality control: Create DNA proficiency panels, IS for HPV16 antibodies, and explore reagent distribution partnerships.

Overall, the workshop served as a model for future HPV LabNet activities, emphasizing the urgent need for international harmonization in lab methodologies to support HPV vaccine effectiveness and prevention.